Dr Ramaswami talks to ecancer at ASCO 2025 about a phase I/II study she presented evaluating the safety and efficacy of abemaciclib, a CDK4/6 inhibitor, in people with HIV-associated and HIV-negative Kaposi sarcoma.

These results suggest that abemaciclib is a well-tolerated and active therapeutic option for Kaposi sarcoma, particularly in patients with previously untreated disease.

The manageable safety profile and high response rates support further investigation of CDK4/6 inhibition as a treatment approach in this patient population.